Tempest Therapeutics Inc. (TPST)
NASDAQ: TPSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TPST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.74M
- EPS (TTM)
- -$3.16
- Dividend yield
- None
- 52-week range
- 0.28 – 4.22
- Day range
- 0.2803 – 0.2968
- Volume / Avg
- 145.31K / 2.56M
- Beta
- —
- Shares outstanding
- 20.00M
52-week range
TPST stock today
Tempest Therapeutics (TPST) closed at $0.287 on Nov 20, down 6.18% (-$0.0189), versus the S&P 500's 3.70% decline. Trading was light, with 145.31K shares changing hands, about 6% of the average daily volume. Shares are 93.2% below their 52-week high of $4.22, set on Nov 24, 2025 and 2.5% above the 52-week low of $0.28, near the bottom of the past year's range.
TPST is down 90.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 91.8%. Tempest Therapeutics has posted a net loss over the last twelve months (EPS of -$3.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tempest Therapeutics
Company profileTempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Matthew Angel Ph.D.
- Headquarters
- Brisbane, CA
- Employees
- 4
- Website
- tempesttx.com
Financial highlights
Full financialsTempest Therapeutics reported a net loss of $26.3 million, compared with a loss of $41.8 million a year earlier. Diluted earnings per share came in at -$6.33.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-26.26M | $-41.84M | $-29.49M | $-35.71M | $-28.30M |
| EPS (diluted) | $-6.33 | $-19.50 | $-1.91 | $-3.09 | $-7.47 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$7.00+2339.02%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.21 vs $-0.32
- Surprise
- +34.38%
TPST news
All TPST news- Tempest Therapeutics, Inc. Receives Nasdaq Delisting Notification on November 17, 2026Nasdaq
- Tempest Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D CandidateGlobeNewswire
- Tempest Therapeutics Receives Nasdaq Notice of Bid Price Below $1.00Nasdaq
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets ExpertiseGlobeNewswire
Tempest Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LGVNLongeveron Inc. Class A | 1.66 | -8.79% | $5.60M | vs TPST |
| XCURExicure Inc. | 0.9001 | -12.82% | $5.89M | vs TPST |
| TOVXTheriva Biologics Inc. | 0.12 | -6.25% | $5.51M | vs TPST |
| ENVBEnveric Biosciences Inc. | 1.35 | -4.26% | $6.04M | vs TPST |
| UPCUniverse Pharmaceuticals Inc. Class A | 1.08 | -20.59% | $5.43M | vs TPST |
| ADXNAddex Therapeutics Ltd ADR | 3.47 | +2.06% | $6.08M | vs TPST |
| CNSPCNS Pharmaceuticals Inc. | 3.56 | -12.75% | $5.25M | vs TPST |
| ACXPAcurx Pharmaceuticals Inc. | 1.04 | +0.97% | $6.30M | vs TPST |
Indexes, lists and sector
Tempest Therapeutics stock FAQ
What is Tempest Therapeutics's stock price today?
TPST last traded at $0.287 as of Nov 20, 4:00 PM EST, down 6.18% on the day. Prices are delayed at least 15 minutes.
Does Tempest Therapeutics pay a dividend?
No. Tempest Therapeutics does not currently pay a regular cash dividend.
Who is Tempest Therapeutics's CEO?
Dr. Matthew Angel Ph.D. is the chief executive officer of Tempest Therapeutics Inc., which has about 4 employees.
Has TPST ever split its stock?
Yes. The most recent TPST stock split was a 1-for-13 split on Apr 9, 2025, one of 3 splits on record.
What is the TPST 52-week high?
The 52-week high for TPST is $4.22 and the 52-week low is $0.28. The stock is currently 93.2% below its high.